The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
Open accessAbstract
Dysregulated activation of the CDK4/6 kinases is a hallmark of most mammary-derived carcinomas. ATP-competitive inhibitors against this complex have been recently advanced in the clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). However, resistance to these compounds has begun to emerge often months to years after their initiation. We investigated potential mechanisms of resistance using cell line models that are highly sensitive to this class of drugs. After prolonged exposure to the selective and potent CDK4/6 inhibitor LY2835219, clones emerged and several were found to harbor amplification of the CDK6 kinase. Amplification of CDK6 resulted in a marked increase in CDK6 expression and reduced response of the CDK4/6 target, phospho-Rb (pRb), to CDK4/6 inhibitors. Knockdown of CDK6 restored drug sensitivity, while enforced overexpression of CDK6 was sufficient to mediate drug resistance. Not only did CDK6 overexpression mediate resistance to CDK4/6 inhibitors but it also led to reduced expression of the ER and progesterone receptor (PR), and diminished responsiveness to ER antagonism. The reduced ER/PR expression after CDK4/6 inhibitor resistance was additionally observed in tumor biopsy specimens from patients treated with these drugs. Alternative mechanisms of resistance to CDK4/6 inhibitors such as loss of pRb and cyclin E1 overexpression also exhibited decreased hormone responsiveness, suggesting that the clinical paradigm of sequential endocrine-based therapy may be ineffective in some settings of acquired CDK4/6 resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
CDK-Independent Activation of Estrogen Receptor by Cyclin D1
Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., & Michalides, R. J. A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81879-6 · Cited by 720
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204 · cited 1×
“CDK6 is known to have kinase independent functions 28, 29 ; however the close correlation between the dose of kinase inhibitor causing loss of pRb and the dose blocking cell proliferation supports the premise that the kinase function of CDK6 is essential for resistance.”
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.534 · Cited by 42
Cited by
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508
Self-citationTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Metadata
- Authors
- Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S.
- Venue
- Oncogene
- Published
- 2016-10-17
- Volume
- 36
- Issue
- 16
- Pages
- 2255-2264
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2537675006
- Cited by
- 415
- References
- 10
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. https://app.cochat.ai/papers/10.1038/onc.2016.379
- The paper
- Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017). Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. https://doi.org/10.1038/onc.2016.379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.